Erasca released preliminary clinical data for ERAS-0015, reporting tumor shrinkage in subsets of patients with advanced pancreatic cancer and advanced non-small cell lung cancer. The company said the results exceeded its expectations, with 40% of pancreatic patients showing tumor shrinkage and 62% of lung patients showing shrinkage. The datasets come from studies conducted in the US and China, and Erasca emphasized that the data are still preliminary. The company also framed tolerability and clinical benefit as favorable relative to what’s known for daraxonrasib, a similar RAS-targeting drug that recently reported overall survival improvements. In the market narrative, ERAS-0015’s release follows heightened attention after Revolution Medicines’ daraxonrasib data, with the competitive landscape now set up for ongoing head-to-head evaluation of efficacy signals and durability. For RAS-targeted therapies, even early topline readouts can shift investor and clinical interest—particularly in pancreatic cancer, where response rates and survival improvements remain key unmet needs.